The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK
Open Access
- 2 June 2011
- journal article
- research article
- Published by BMJ in Sexually Transmitted Infections
- Vol. 87 (6), 458-463
- https://doi.org/10.1136/sextrans-2011-050073
Abstract
Objectives To estimate the loss of quality of life and cost of treatment associated with genital warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case note review of individuals with genital warts, carried out in eight sexual health clinics in England and Northern Ireland. Individuals with genital warts attending the participating clinics were invited to take part in the questionnaire study. 895 participants were recruited. A separate sample of 370 participants who had attended a participating clinic with a first visit for a first or recurrent episode of genital warts between April and June 2007 was included in the case note review. Quality of life was measured using the EQ-5D questionnaire and the cost of an episode of care was derived from the case note review. Results The weighted mean EQ-5D index score was 0.87 (95% CI 0.85 to 0.89). The weighted mean disutility was 0.056 (95% CI 0.038 to 0.074). The estimated mean loss of quality-adjusted life-years associated with an episode of genital warts was 0.018 (95% CI 0.0079 to 0.031), equivalent to 6.6 days of healthy life lost per episode. The weighted mean cost per episode of care was £94 (95% CI £84 to £104), not including the cost of a sexually transmitted infection screen. Conclusions Genital warts have a substantial impact on the health service and the individual. This information can be utilised for economic evaluation of human papillomavirus vaccination.Keywords
This publication has 30 references indexed in Scilit:
- Genital warts and cost of care in EnglandSexually Transmitted Infections, 2011
- Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance dataThe Lancet Infectious Diseases, 2011
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in EnglandBritish Journal of Cancer, 2010
- Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young womenSexually Transmitted Infections, 2009
- Incidence, prise en charge et coût des condylomes acuminés anogénitaux chez les femmes consultant leur gynécologue en FranceGynécologie Obstétrique & Fertilité, 2007
- Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UKCurrent Medical Research and Opinion, 2006
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Physical and Psychological Effects of Anogenital Warts on Female PatientsSexually Transmitted Diseases, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990